Daonil M

There is no image.

Method of action: Drugs Used In Diabets, Hypoglycemic, Lipid-Lowering

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Daonil M

Quick Facts

Property	Description
Active ingredient	Glibenclamide, Metformin Hydrochloride
Form	Oral tablet (often sustained-release)
Pharmacological class	Antihyperglycemic agent (Antidiabetic)
Common use	Management of Type 2 diabetes mellitus
Origin	Synthetic combination product

What Type of Medicine is Daonil M? (Identity and Classification)

Daonil M is a prescription-only oral medication classified as an antihyperglycemic agent used to manage Type 2 diabetes mellitus in adults. It is a synthetic drug supplied typically as a tablet and is categorized as a fixed-dose combination (FDC) product. This FDC structure means it contains two distinct active ingredients in a single formulation, a therapeutic strategy for effective glucose management. This approach is a well-established method in endocrinology for patients who require more than one mechanism to achieve optimal glycemic control.

Composition: Combining Glibenclamide and Metformin

The medication is composed of two different pharmacological classes: Glibenclamide (a sulfonylurea) and Metformin Hydrochloride (a biguanide). Glibenclamide functions as an insulin secretagogue, prompting the pancreas to release more insulin. Metformin Hydrochloride acts as an insulin sensitizer, enhancing the ability of tissues to use insulin while also reducing the amount of glucose produced by the liver. The dual-action approach employed by this composition demonstrates therapeutic action against hyperglycemia.

What is the General Purpose of Daonil M? (Therapeutic Aim)

The core purpose of Daonil M is to achieve and maintain better glycemic control in patients with non-insulin-dependent diabetes. The combination therapy helps to lower elevated blood sugar levels through these complementary mechanisms. This strategic combination ensures a robust and effective therapeutic strategy against the progression of the condition. Its typical use is for adults whose blood sugar remains too high despite diet and exercise alone.

What side effects are possible with Daonil M?

Possible side effects and safety information

The safety profile of the Glibenclamide/Metformin combination is based on the known regulatory classifications for its components as documented by official government sources, including the EMA and FDA. Adverse reactions are classified by frequency and the physiological systems they affect.

Documented Frequency and System-Organ Classes

The most frequently encountered adverse reactions are classified as Very Common and primarily affect the Gastrointestinal System. These include disturbances such as diarrhoea, nausea, vomiting, and loss of appetite. These effects are often noted to be more frequent at the start of treatment and during dose escalation.

Reactions classified as Common include hypoglycaemia (low blood sugar), which is characteristic of the Glibenclamide component, and taste disturbance (e.g., metallic taste). Uncommon or Rare effects involve the Skin and Subcutaneous Tissue (e.g., pruritus, urticaria, photosensitivity) and Blood and Lymphatic System (e.g., leukopenia).

Serious Safety Considerations

The most serious adverse reaction documented is Lactic Acidosis, classified as Very Rare. This is a life-threatening metabolic complication associated with the Metformin component. The risk of this reaction increases substantially in patients with underlying renal impairment (kidney issues). Severe Hypoglycaemia is also a documented serious risk, particularly when meals are missed or following unusually heavy exercise.

Safety Constraints

Official labeling defines specific restrictions for use. The medicine is contraindicated in cases of severe renal impairment and severe hepatic impairment (liver issues). Safety statements also note that older adults may be more susceptible to serious risks due to potential age-related decline in organ function.

Overdose and Emergency Response

The official regulatory documents state that an overdose of the Glibenclamide and Metformin combination is primarily characterized by two distinct, severe metabolic complications.

Documented Overdose Manifestations

Primary Component	Severe Outcome and Manifestations
Glibenclamide	Severe, Prolonged Hypoglycemia, which may lead to seizures or hypoglycemic coma. Early signs can include drowsiness, nausea, and dizziness.
Metformin HCl	Lactic Acidosis, a serious, life-threatening metabolic complication. Manifestations often include nonspecific symptoms such as abdominal pain, somnolence, myalgias, and acidotic dyspnea (deep, rapid breathing).

Required Emergency Action

Any suspected overdose requires that the medication be immediately discontinued. Patients should seek immediate medical attention and require immediate hospitalization for management. The regulatory guidance mandates the administration of intravenous glucose solution for severe hypoglycemic reactions.

For established lactic acidosis, prompt hemodialysis is the described procedural intervention to aid in drug removal and correct the severe acidosis. It is officially noted that the risk of these severe outcomes is increased in patients with renal impairment or those who are 65 years or greater in age.

Therapeutic Uses of Daonil M

What Daonil M Treats: Main Uses and Benefits

The core therapeutic purpose of Daonil M is applied in the management of a specific chronic condition, Type 2 Diabetes Mellitus. This medication is relevant for easing symptoms related to systemic imbalance in situations involving certain distressing symptoms. It is used for managing conditions presenting with episodic or fluctuating manifestations and those associated with acute or disruptive episodes.

Managing Fluctuating Symptom Patterns

Daonil M is used across conditions where symptoms may intensify temporarily. It helps address symptom clusters that may become intense or disruptive, used when symptoms create noticeable physiological strain. The medicine is used during phases of increased distress or discomfort, where supportive symptom management is appropriate. This provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

"This combination is applied across domains where additional symptomatic support is needed, and supports the patient during difficult episodes by easing distress."

Addressing Symptomatic Interference

This medicine is relevant when symptoms related to the condition create noticeable interference with daily stability. It is helpful in situations requiring additional symptomatic assistance and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relevant for managing symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for the combination product Daonil M (Glibenclamide/Metformin) is strictly defined by regulatory documents, primarily for adults with Type 2 Diabetes Mellitus whose blood sugar is inadequately controlled by other means.

The medicine is contraindicated and must not be used in patients with severe renal impairment ( eGFR < 30 mL/min/1.73 m^2), Type 1 Diabetes Mellitus, or any form of acute metabolic acidosis, which includes lactic acidosis or diabetic ketoacidosis. Absolute exclusions also apply to patients with known hypersensitivity to the components, severe hepatic dysfunction, or acute conditions causing tissue hypoxia, such as unstable heart failure or shock.

Regarding life stage, the medicine is contraindicated during both pregnancy and lactation, with official guidance recommending a switch to insulin therapy. Use is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established. For older adults, caution and frequent renal function monitoring are required. Furthermore, use must be temporarily discontinued before certain major surgery and radiological procedures involving iodinated contrast media.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Daonil M (Glibenclamide and Metformin Hydrochloride) based strictly on regulatory prescribing information. Interactions are categorized by their effect on drug exposure or on blood glucose control.

Restrictions and Prohibitions

Category	Regulatory Requirement
Iodinated Contrast Agents	Metformin must be temporarily discontinued prior to or at the time of intravascular administration and not restarted until at least 48 hours later.
Colesevelam	Daonil M must be administered at least four hours prior to Colesevelam to avoid reduced Glibenclamide absorption.
Alcohol	Excessive alcohol intake is classified as a risk factor for lactic acidosis, due to potentiation of Metformin's effect on lactate metabolism.

Pharmacodynamic and Exposure-Altering Agents

Co-administration with cationic drugs (e.g., Cimetidine, Ranolazine) may increase Metformin accumulation by interfering with its renal clearance. Carbonic Anhydrase Inhibitors (e.g., Topiramate) may also increase the risk of lactic acidosis. Agents that can acutely impair renal function, such as NSAIDs and certain Diuretics, necessitate caution due to the risk of Metformin accumulation.

Additionally, other glucose-lowering agents may cause a potentiated hypoglycemic effect, while medicinal products with intrinsic hyperglycemic activity (e.g., Glucocorticoids) may reduce the drug’s effectiveness. Beta-blockers may mask the symptoms of hypoglycemia.

Mechanism of Action

Daonil M is a fixed-dose combination product containing glibenclamide (a sulfonylurea) and metformin (a biguanide). Its mechanism involves two distinct pathways targeting cellular energy metabolism and insulin release.

Glibenclamide Pathway

Glibenclamide acts on the pancreatic beta-cells. Its primary biological target is the sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium ( K ATP) channel. Glibenclamide functions as an inhibitor by binding to SUR1. This interaction closes the K ATP channel, preventing the efflux of potassium ions. The subsequent intracellular consequence is beta-cell membrane depolarization. This depolarization opens voltage-gated Ca^2+ channels, resulting in an influx of Ca^2+ ions. The downstream cascade involves the Ca^2+-dependent stimulation of insulin-containing granule fusion with the plasma membrane, leading to an increased systemic release of insulin.

Metformin Pathway

Metformin selectively accumulates in the liver (hepatocytes) and the gastrointestinal tract. Its primary molecular target is the inhibition of the mitochondrial respiratory chain complex I. This inhibition decreases adenosine triphosphate ( ATP) production, resulting in a fall in the cellular ATP/ adenosine monophosphate ( AMP) ratio. The altered ratio activates AMP-activated protein kinase ( AMPK) kinase, functioning as a cellular energy sensor. Activated AMPK is the central intracellular consequence, which in turn phosphorylates downstream substrates. These substrates inhibit pathways required for gluconeogenesis, specifically suppressing the expression and activity of key hepatic enzymes, resulting in a systemic physiological modulation: a reduction in endogenous hepatic glucose production.

Dosage and Administration Information

How to Use Daonil M: Official Administration Guidelines

The usage of the Glibenclamide and Metformin fixed-dose combination (Daonil M) is governed by specific instructions focusing strictly on administration protocol and dosing structure.

Administration Scope

Instruction	Details
Route of administration	The medication is intended for oral administration only and must be swallowed.
Dosing schedule	Treatment typically begins with the lowest available strength (e.g., 1.25 mg / 250 mg). The maximum daily dose should not exceed 20 mg Glibenclamide / 2000 mg Metformin.
Timing in relation to meals	Tablets must be taken with meals, usually in divided doses such as with breakfast and dinner, to match individual eating habits and support tolerability.
Preparation requirements	Sustained-release formulations must not be crushed or chewed.
Age-group administration rules	The medicine is approved for adult use only. Dosage adjustments for older adults require careful assessment of kidney function.
Missed-dose rules	If a dose is missed, it should not be doubled to compensate; the next dose should be taken at the usual time.
Special procedural conditions	The dosage must be gradually titrated, with dose increases permitted no more often than every one to two weeks. Use is contraindicated when kidney function, measured by eGFR, is below 30 mL/min/1.73 m^2.

Connection to the Overall Use Protocol

The official protocol dictates a usage pattern that is strictly oral and meal-time dependent, starting with a low dose and increasing slowly over a multi-week period until the necessary level is achieved. This procedural structure is fundamentally constrained by defined maximum dose limits and specific kidney function thresholds that govern the initiation and continuation of treatment.

Recent Clinical Evidence

Clinical Evidence: Daonil M

Daonil M is a fixed-dose combination of glibenclamide (a sulfonylurea) and metformin (a biguanide) used in the management of type 2 diabetes mellitus.

Clinical research has focused on the combination's impact on glycemic control, particularly when diet, exercise, and single-drug therapy (monotherapy) have not provided adequate results.

Glycemic Control and Key Findings

Studies comparing the fixed-dose combination to monotherapy with either glibenclamide or metformin alone suggest that the combination is generally associated with greater changes in glycemic markers, including a reduction in Glycated Hemoglobin (HbA1c) levels. Specific findings from trials include:

Outcome Measured	Trial Findings (vs. Monotherapy)
HbA1c Reduction	Combination use was associated with greater absolute reductions in HbA1c percentage points.
Fasting Plasma Glucose (FPG)	Combination use was associated with greater reductions in FPG levels.
Dose Reduction	The use of the fixed-dose tablet may allow for the use of lower average doses of each component drug compared to taking them separately, while still achieving targeted glycemic outcomes.

Safety and Tolerability

Clinical trials also examined the safety profile and tolerability of the combination. The most frequently observed adverse event across multiple studies was hypoglycemia (low blood sugar), which is a known risk associated with glibenclamide use. Gastrointestinal issues, such as nausea, diarrhea, and stomach discomfort, were also commonly reported in trial participants, consistent with the known effects of metformin.

Frequently Asked Questions (FAQ)

Common questions about Daonil M (FAQ)

Q: What is the difference between Daonil M and taking Metformin and Glibenclamide separately?

Official clinical studies indicate that using the fixed-dose combination (FDC) tablet may allow for the use of lower average doses of the two components compared to when they are taken as two separate tablets. Despite the difference in dosing structure, the FDC is associated with results aligned with target glycemic goals, according to official reports.

Q: Has Daonil M been studied in people with heart conditions?

Regulatory documents define specific safety constraints regarding heart health. For instance, the medicine is contraindicated (must not be used) in acute conditions that cause tissue hypoxia, such as unstable heart failure or shock. The risk of the very rare, but serious, complication called lactic acidosis is described in official labeling as being higher in patients with certain heart problems.

Q: Does taking Daonil M typically cause weight gain or weight loss?

The two components of Daonil M have known effects on weight according to official product information. The Glibenclamide component, a sulfonylurea, is generally associated with weight gain. Conversely, the Metformin component is often associated with loss of appetite, a side effect that is documented as being linked to weight stabilization or modest loss.

Q: What are the signs of lactic acidosis related to the Metformin component of Daonil M?

Lactic acidosis is a very rare but serious adverse reaction associated with Metformin. The onset is often described as subtle, featuring non-specific symptoms such as increasing sleepiness, muscle aches (myalgias), trouble breathing (respiratory distress), and feeling unwell (malaise). If these signs are observed, official documents advise seeking medical attention immediately.

Q: Does Daonil M interact with blood pressure medications?

Yes, official prescribing information indicates the potential for interaction with certain medications commonly used for blood pressure. For example, some diuretics (water pills) may affect kidney function, and beta-blockers may mask the symptoms of low blood sugar, necessitating careful observation.

Q: What does official research say about the long-term outcomes of patients using Daonil M?

Official clinical evidence focuses primarily on the effectiveness of the combination in achieving glycemic control. Studies report that using Daonil M is generally associated with greater reductions in blood sugar markers, specifically Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG), compared to using only one of the active ingredients alone.

Q: Are there any over-the-counter medicines or supplements that interact with Daonil M?

Regulatory documents warn that interactions may occur with certain types of medicines, even those available over-the-counter. This includes products that are classified as cationic drugs (which can increase Metformin levels) or drugs with intrinsic hyperglycemic activity (which could reduce Daonil M's effectiveness).

Q: What is the risk of vitamin B12 deficiency while on long-term Daonil M therapy?

Official product warnings related to the Metformin component indicate that long-term use may lower Vitamin B12 levels in the body. Official guidance describes the need for B12 level monitoring in patients using the drug, particularly in individuals who develop symptoms like anemia or peripheral neuropathy (nerve pain).

Q: Is there a link between Daonil M and increased risk of pancreatitis?

Pancreatitis (inflammation of the pancreas) is not listed as a common or rare adverse reaction in the authoritative regulatory documents. Although not listed on the core safety table, its occurrence has been observed in post-marketing case reports related to the Metformin component.

Q: Is it normal to feel slightly dizzy or lightheaded when adjusting to Daonil M?

Regulatory data reports dizziness and headache as common adverse events during treatment. These sensations may be related to the body adjusting to the medication or could be a sign of hypoglycemia (low blood sugar), which is a common risk. They could also, rarely, be an initial symptom of lactic acidosis.

Q: Does Daonil M interact with commonly prescribed antidepressants?

Specific interactions with the entire class of antidepressants are not detailed as a dedicated warning in the regulatory documentation. However, official information notes that many medications can affect blood glucose control. Official information notes that patients are advised to inform a healthcare provider of all medications, as certain agents can affect blood glucose control.

Q: Does taking Daonil M affect fertility in men or women?

Official information related to females of reproductive potential is included in regulatory documents. It advises premenopausal females to be aware of the potential for an unintended pregnancy, as the improvement of blood sugar control can sometimes restore regular ovulation.

Q: What is the difference between Daonil M and other common combination diabetes drugs?

Daonil M is classified as a fixed-dose combination containing an insulin secretagogue, Glibenclamide, and an insulin sensitizer, Metformin. This dual-mechanism approach places it in a distinct pharmacological class compared to other combination drugs available for the management of Type 2 diabetes.

Q: Is the name Daonil M used in all countries?

The specific brand name Daonil M and its corresponding regulatory documentation are often used in specific regions, such as parts of Asia or Africa. While the active ingredients (Glibenclamide and Metformin) are used worldwide, they are generally marketed under many different local and regional brand names.

How should Daonil M be stored and disposed of?

Official Storage and Disposal Conditions for Daonil M

Daonil M (glibenclamide and metformin hydrochloride) must be stored and handled according to specific requirements documented in regulatory labeling to maintain its quality.

Item	Official Regulatory Requirement
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (or below 30 C), and keep from freezing.
Protection	Must be protected from light and moisture (or excess heat).
Packaging	Keep in the original container, ensure it is tightly closed, and do not use past the expiration date.
Child-Safety	Keep out of the reach and sight of children in a secure location.
Disposal	Dispose of unused or expired medicine through a community drug take-back program. If unavailable, mix with an undesirable substance (e.g., coffee grounds) in a sealed container before placing in household trash. Do not flush down the toilet.